Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study.

Clicks: 183
ID: 264520
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a rare potential immune-related adverse event (irAE) of checkpoint inhibitors. PRES is a disorder that has a variety of clinical and radiological features, which makes it a challenge for advanced practice registered nurses to diagnose. IrAEs such as PRES require prompt recognition and intervention to optimize clinical outcomes.
Reference Key
barberidentificationasiapacific Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Barber, Fedricker D;
Journal Asia-Pacific journal of oncology nursing
Year Year not found
DOI
10.4103/apjon.apjon_49_20
URL
Keywords
checkpoint inhibitors phase i clinical trial posterior reversible encephalopathy syndrome

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.